|
NL9201440A
(nl)
|
1992-08-11 |
1994-03-01 |
Univ Leiden |
Triantennaire clusterglycosiden, hun bereiding en toepassing.
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
JP4236812B2
(ja)
|
1997-09-12 |
2009-03-11 |
エクシコン エ／エス |
オリゴヌクレオチド類似体
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
US7053207B2
(en)
|
1999-05-04 |
2006-05-30 |
Exiqon A/S |
L-ribo-LNA analogues
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
CA2429814C
(en)
|
2000-12-01 |
2014-02-18 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
|
WO2003040395A2
(en)
|
2001-11-07 |
2003-05-15 |
Applera Corporation |
Universal nucleotides for nucleic acid analysis
|
|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
ATE443765T1
(de)
|
2003-03-21 |
2009-10-15 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US7560544B2
(en)
|
2004-12-17 |
2009-07-14 |
Anadys Pharmaceuticals, Inc. |
3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
WO2007090071A2
(en)
|
2006-01-27 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
WO2007085485A2
(en)
|
2006-01-27 |
2007-08-02 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
DK2173760T4
(en)
|
2007-06-08 |
2016-02-08 |
Isis Pharmaceuticals Inc |
Carbocyclic bicyclic nukleinsyreanaloge
|
|
AU2008272918B2
(en)
|
2007-07-05 |
2012-09-13 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
WO2009067647A1
(en)
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
|
DK2341943T3
(en)
|
2008-09-22 |
2019-02-25 |
Dicerna Pharmaceuticals Inc |
COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS
|
|
US8691971B2
(en)
|
2008-09-23 |
2014-04-08 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
|
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
|
KR101728655B1
(ko)
|
2008-12-18 |
2017-04-19 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
US9012421B2
(en)
|
2009-08-06 |
2015-04-21 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
EP2580228B1
(en)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US10202599B2
(en)
|
2011-08-11 |
2019-02-12 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
SG11201501255PA
(en)
*
|
2012-08-30 |
2015-03-30 |
Replicor Inc |
Methods for the treatment of hepatitis b and hepatitis d infections
|
|
CN104837996A
(zh)
|
2012-11-15 |
2015-08-12 |
罗氏创新中心哥本哈根有限公司 |
抗apob反义缀合物化合物
|
|
EP2928877B1
(en)
|
2012-12-06 |
2020-01-22 |
Merck Sharp & Dohme Corp. |
Disulfide masked prodrug compositions and methods
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
HUE048738T2
(hu)
|
2013-06-27 |
2020-08-28 |
Roche Innovation Ct Copenhagen As |
Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
|
|
AU2015226206B2
(en)
|
2014-03-07 |
2017-03-16 |
F. Hoffmann-La Roche Ag |
Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
CA2950960A1
(en)
|
2014-06-06 |
2015-12-10 |
Solstice Biologics, Ltd. |
Polynucleotide constructs having bioreversible and non-bioreversible groups
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
JP2017531655A
(ja)
|
2014-10-11 |
2017-10-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
感染性疾患の処置に使用するための化合物
|
|
KR102545316B1
(ko)
|
2014-11-10 |
2023-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
|
|
SG11201704512PA
(en)
|
2014-12-08 |
2017-07-28 |
Hoffmann La Roche |
3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
|
|
DK3569711T3
(da)
|
2014-12-15 |
2021-02-22 |
Dicerna Pharmaceuticals Inc |
Ligandmodificerede dobbeltstrengede nukleinsyrer
|
|
CA2979490C
(en)
*
|
2015-03-16 |
2023-07-18 |
F. Hoffmann-La Roche Ag |
Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
|
|
JP6806709B2
(ja)
*
|
2015-05-12 |
2021-01-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
WO2017211791A1
(en)
*
|
2016-06-07 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
|
US11504391B1
(en)
|
2016-11-23 |
2022-11-22 |
Alnylam Pharmaceuticals, Inc. |
Modified RNA agents with reduced off-target effect
|
|
AU2018205995B2
(en)
*
|
2017-01-06 |
2021-09-23 |
F. Hoffmann-La Roche Ag |
Solid forms of [(1S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
|
|
UA128786C2
(uk)
*
|
2017-10-20 |
2024-10-23 |
Дайсерна Фармасьютикалз, Інк |
Олігонуклеотид для лікування інфекції гепатиту в
|